List of Excipients in Branded Drug FLUPHENAZINE DECANOATE

« Back to Dashboard

Generic Drugs Containing FLUPHENAZINE DECANOATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	fluphenazine decanoate	0143-9529	BENZYL ALCOHOL
Hikma Pharmaceuticals USA Inc	fluphenazine decanoate	0143-9529	SESAME OIL
Sagent Pharmaceuticals	fluphenazine decanoate	25021-838	BENZYL ALCOHOL
Sagent Pharmaceuticals	fluphenazine decanoate	25021-838	SESAME OIL
Endo USA Inc	fluphenazine decanoate	42023-129	BENZYL ALCOHOL
Endo USA Inc	fluphenazine decanoate	42023-129	SESAME OIL

What are the Most Frequently-Used Excipients in FLUPHENAZINE DECANOATE?

# Of NDCs	Excipient
10	BENZYL ALCOHOL
10	SESAME OIL

Fluphenazine Decanoate Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Fluphenazine decanoate is a long-acting, oil-based injectable antipsychotic with limited current competition, mature clinical use, and no meaningful composition-of-matter exclusivity. Commercial value is concentrated in reliable depot manufacturing, injection tolerability, supply continuity, preservative strategy, and differentiated presentations rather than in new active-ingredient patents. The main opportunities are generic injectable entry, contract manufacturing, low-volume regional supply, improved packaging, and lifecycle products with better administration characteristics.

What is fluphenazine decanoate and how is it formulated?

Fluphenazine decanoate is the decanoate ester prodrug of fluphenazine, a first-generation antipsychotic in the phenothiazine class. It is administered intramuscularly as a long-acting depot suspension for maintenance treatment of patients requiring prolonged parenteral therapy.

The decanoate ester has very low aqueous solubility. Commercial products therefore use an oil vehicle rather than an aqueous solution. The historical product formulation is based on sesame oil and includes an antioxidant, commonly ascorbic acid, to support chemical stability. The formulation is intended for deep intramuscular injection and is supplied in multi-dose vial configurations in some markets. The U.S. label identifies the product as a sterile injectable solution or depot preparation, depending on the product and labeling presentation. [1]

Formulation attribute	Commercial significance
Active ingredient	Fluphenazine decanoate
Dosage form	Long-acting intramuscular depot injection
Solubility profile	Poor water solubility favors an oil vehicle
Typical vehicle	Sesame oil in historical U.S. products
Antioxidant strategy	Ascorbic acid or another qualified antioxidant may be used
Administration	Deep intramuscular injection
Storage	Controlled room-temperature conditions under product labeling
Primary quality risks	Assay, degradation, sterility, particulate matter, viscosity, syringeability, and injection-site tolerability

The critical excipient objective is not rapid dissolution. It is controlled solubilization or dispersion of the decanoate ester, chemical stability over shelf life, and reproducible delivery from the vial or syringe.

What excipients are used in fluphenazine decanoate injections?

The principal excipient strategy is an anhydrous or low-water oil system supported by an antioxidant and sterile container-closure system.

Oil vehicle

Sesame oil has a long history in depot intramuscular products. It can provide suitable solubilization for lipophilic ester drugs and has established pharmaceutical precedent. Its disadvantages include variability in fatty-acid composition, oxidation risk, patient sensitivity, viscosity, and potential supply qualification requirements.

Alternative oils may include refined vegetable oils or medium-chain triglycerides. A substitution would require comparative pharmaceutical development because the oil affects:

• Drug solubility and precipitation risk
• Viscosity and injection force
• Syringeability through the intended needle gauge
• Depot formation and release rate
• Oxidative stability
• Local tissue tolerability
• Extractables and leachables
• Container compatibility

A change from sesame oil to a synthetic or highly standardized vehicle could create a meaningful product differentiation opportunity, but it would also increase regulatory and clinical development requirements.

Antioxidants

Oxidation control is a central formulation issue. Ascorbic acid has been used in historical fluphenazine decanoate products. Other antioxidant systems could be evaluated, but selection must account for oil-phase distribution, pH behavior in residual water, compatibility with the active ingredient, and injectable safety.

Potential development options include:

• Tocopherol-based antioxidant systems
• Ascorbyl derivatives with improved oil compatibility
• Low-level combinations of antioxidants
• Oxygen-reduced filling and nitrogen overlay
• Light-protective packaging
• Lower peroxide excipient specifications

An antioxidant change can affect impurity formation, color, particulate generation, and extractables. It may require a substantial comparability package even when the product remains pharmaceutically equivalent.

Preservatives

A multidose oil-based injectable may require antimicrobial preservation unless the container and use pattern support an alternative strategy. Preservative selection is constrained by injection-site tolerability and compatibility with the oil vehicle.

A single-dose presentation can avoid or reduce preservative exposure. This creates a commercial opportunity for hospitals and outpatient settings that prioritize simplified handling, reduced contamination risk, and lower medication-preparation burden.

Packaging-related materials

The formulation cannot be separated from the container-closure system. Relevant components include:

• Type I glass vials
• Elastomeric stoppers
• Aluminum seals
• Prefilled syringes
• Needle systems
• Light-protective secondary packaging

Oil-based products can extract or interact with elastomer components. Long-term studies should examine stopper swelling, seal integrity, sorption, volatile loss, and particulate formation. Prefilled syringes require further evaluation of silicone oil, glide force, needle compatibility, and drug contact with syringe components.

What formulation patents protect fluphenazine decanoate?

The principal patent barrier for fluphenazine decanoate has expired because the product was introduced decades ago. Current commercial protection is therefore unlikely to depend on an active composition-of-matter patent.

The historical Prolixin and fluphenazine decanoate product franchises were associated with the originator, formerly Bristol-Myers Squibb and later other commercial owners. The drug is now marketed in generic form in the United States and other jurisdictions. The relevant commercial barriers are manufacturing know-how, regulatory approval, sterile-facility capacity, and product reliability.

IP category	Current commercial relevance
Active ingredient patent	Expired
Decanoate ester patent	Expired or commercially obsolete
Original depot formulation	Historical protection expired
Method-of-use patents	Limited practical value for an established generic indication
Manufacturing patents	Potentially relevant only for new processes or improved presentations
Packaging patents	Possible for proprietary delivery systems
New formulation patents	Available for genuinely novel excipient systems or devices
Trademark protection	May remain relevant to brand identity but does not block generic entry

A new patent strategy could target a specific formulation or delivery system rather than the active ingredient. Patentable subject matter may include a defined oil blend, a narrow antioxidant system, a low-viscosity formulation, a prefilled device, or a formulation that improves stability under controlled stress conditions. Broad claims covering “fluphenazine decanoate in oil” would face substantial prior-art risk.

When does fluphenazine decanoate lose exclusivity?

Fluphenazine decanoate lost practical market exclusivity many years ago. The product is not a current new chemical entity, and standard five-year NCE exclusivity is not relevant. The product also does not have the regulatory profile of a biologic, so biosimilar pathways do not apply.

The relevant FDA route for a new generic injectable is generally an abbreviated new drug application, supported by pharmaceutical equivalence, bioequivalence or applicable product-specific evidence, sterility controls, stability data, and manufacturing compliance. FDA requirements depend on the reference product, dosage form, route, and formulation.

Does fluphenazine decanoate have Orange Book exclusivity?

Fluphenazine decanoate is an FDA-approved small-molecule drug product, not a biologic. The Orange Book may identify approved products and therapeutic-equivalence information, but an old generic injectable does not normally carry active innovator exclusivity.

Patent listings should be reviewed product by product because Orange Book records can differ by strength, dosage form, applicant, and reference product. A product-specific patent listing does not automatically establish a blocking right against every formulation or every manufacturer. [2]

Are Paragraph IV challenges relevant to fluphenazine decanoate?

Paragraph IV litigation risk is likely low compared with newer branded drugs because the main active-ingredient and formulation barriers are historical. A generic applicant could still file a Paragraph IV certification if an Orange Book-listed patent covered the reference product. The commercial value of such a challenge would depend on:

• Whether an active patent is listed
• The number of approved generic competitors
• The size of the injectable market
• The probability of 180-day exclusivity
• The cost of sterile manufacturing
• The remaining purchasing contracts

For an old depot injectable, the larger risk may be regulatory and operational rather than patent litigation. Deficiencies in sterility assurance, extractables, stability, device performance, or facility inspection status can delay entry without a patent dispute.

What is the FDA regulatory status of fluphenazine decanoate?

Fluphenazine decanoate is an FDA-approved prescription injectable antipsychotic. U.S. labeling identifies it for maintenance treatment of patients requiring prolonged parenteral neuroleptic therapy. The product carries class-related warnings associated with antipsychotic use, including tardive dyskinesia and neuroleptic malignant syndrome. [1]

A new applicant must address the following regulatory issues:

1. Pharmaceutical equivalence to the reference product.
2. Sterility and endotoxin control.
3. Container-closure integrity.
4. In-use stability for multidose presentations.
5. Comparative impurity profiles.
6. Viscosity and deliverability through the labeled needle.
7. Particulate matter.
8. Oil vehicle identity, purity, and oxidation limits.
9. Extractables and leachables.
10. Manufacturing process validation.

For an oil-based depot, conventional aqueous injectable development assumptions do not apply. The sponsor must demonstrate control of physical properties that can influence injection and release.

What excipient strategy offers the strongest commercial opportunity?

The strongest near-term opportunity is a reliable generic formulation that closely matches the established reference product. This strategy minimizes regulatory risk and avoids unnecessary clinical differentiation.

A second opportunity is a preservative-free, single-dose vial. This presentation could appeal to hospitals and clinics seeking lower contamination risk and simpler inventory management. The commercial benefit depends on whether purchasers will pay for unit-dose packaging.

A third opportunity is a prefilled syringe or ready-to-administer presentation. This could reduce preparation steps and dosing errors, but the device and container system would create additional development costs. The sponsor would need to establish compatibility with the viscous oil formulation and demonstrate reliable dose delivery.

A fourth opportunity is a standardized oil vehicle with improved oxidation control. The value proposition would be strongest if the product demonstrates longer shelf life, lower impurity growth, lower injection force, or improved cold-chain resilience.

Opportunity	Differentiation	Regulatory burden	Commercial outlook
Reference-like generic vial	Low	Lowest	Strongest path to entry
Preservative-free single-dose vial	Moderate	Moderate	Attractive institutional niche
Prefilled syringe	High	High	Potential administration advantage
Alternative oil vehicle	Moderate	Moderate to high	Depends on tolerability and equivalence
Improved antioxidant system	Moderate	Moderate	Patent and stability opportunity
Novel sustained-release formulation	High	Very high	Large development and clinical burden

How strong is the patent estate for fluphenazine decanoate?

The estate is weak for blocking purposes but may be open for targeted improvement patents. The active ingredient and established depot concept are old. New claims would need to avoid predictable reformulations and demonstrate a technical effect.

Potentially stronger patent positions could cover:

• A narrowly defined excipient concentration range that materially improves stability
• A specific vehicle with lower injection force and equivalent release
• A device-formulation combination
• A validated low-peroxide oil specification
• A sterile manufacturing process that reduces a defined impurity
• A single-dose presentation with demonstrated stability and container compatibility

Patent strength would depend on claim scope, prior art, enablement, written description, and whether the improvement is clinically or technically meaningful. A formulation patent that merely substitutes one common vegetable oil for another would face a higher obviousness risk.

Which companies are challenging fluphenazine decanoate?

The commercial field is primarily generic and fragmented. The relevant competitors are approved generic injectable manufacturers, contract manufacturers with sterile oil-filling capacity, and regional suppliers. This market is less likely to produce high-profile patent litigation than branded long-acting injectables such as paliperidone palmitate or aripiprazole lauroxil.

The practical competitive questions are:

• Which companies have an approved product?
• Which suppliers maintain active commercial inventory?
• Which manufacturers have FDA-compliant sterile injectable capacity?
• Can the supplier maintain uninterrupted access to pharmaceutical-grade oil and glass components?
• Does the product qualify for hospital purchasing contracts?
• Can the manufacturer support low-volume but recurring demand?

How does fluphenazine decanoate compare with newer long-acting antipsychotics?

Fluphenazine decanoate has a lower cost base and a mature formulation platform, but newer products often have stronger clinical positioning, larger commercial budgets, and more advanced administration intervals.

Product	Active ingredient	Depot technology	Typical competitive advantage
Fluphenazine decanoate	Fluphenazine ester	Oil-based IM depot	Low-cost established option
Haloperidol decanoate	Haloperidol ester	Oil-based IM depot	Broad generic availability
Paliperidone palmitate	Paliperidone ester	Aqueous nanocrystal suspension	Longer dosing intervals and branded support
Aripiprazole monohydrate	Aripiprazole	Aqueous suspension	Branded clinical positioning
Aripiprazole lauroxil	Aripiprazole prodrug	Extended-release injectable system	Long dosing intervals and lifecycle products

The commercial opportunity for fluphenazine decanoate is therefore unlikely to be premium pricing. It is more likely to arise from dependable supply, lower acquisition cost, and operational simplicity.

What generic launch risks exist?

A generic launch can occur without major patent litigation but still fail commercially if the product has supply or quality problems. Key risks include:

• Sterile manufacturing capacity constraints
• Limited market size
• Low reimbursement margins
• Hospital purchasing concentration
• Raw-material variability
• Oil oxidation
• Particulate contamination
• Vial stopper interaction
• Injection-force variability
• Product shortages caused by a single manufacturing site
• Low willingness to switch from an established supplier

Geographic expansion adds country-specific requirements for excipient standards, pharmacopoeial compliance, local labeling, import controls, and stability zones. Sesame oil and other excipients may require different documentation across the United States, European Union, and emerging markets.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve manufacturing and commercialization rights than core drug patents. Potential structures include:

• Regional distribution licenses
• Contract manufacturing agreements
• Technology transfer for sterile oil filling
• Co-development of a preservative-free presentation
• Hospital or government supply contracts
• Authorized generic arrangements
• Private-label supply to specialty distributors

A licensee would place greater value on regulatory status, supply reliability, and manufacturing economics than on an expired patent estate. A differentiated formulation with granted patents could support stronger economics, but the market must justify the cost of development and regulatory review.

What revenue exposure is associated with fluphenazine decanoate?

Public revenue disclosure is limited because fluphenazine decanoate is generally sold as a generic product and is not reported as a major standalone franchise by most manufacturers. The market is likely small relative to newer long-acting antipsychotics, but demand can be durable because some patients remain clinically stable on established depot therapy.

Revenue depends on:

• Institutional utilization
• Generic supplier count
• Product availability
• Reimbursement and tender pricing
• Dose frequency
• Regional treatment standards
• Shortage conditions
• Manufacturer participation in public-sector procurement

The product is best viewed as a stable niche injectable rather than a high-growth branded opportunity.

Key Takeaways

• Fluphenazine decanoate is an old, oil-based long-acting injectable with no meaningful current composition-of-matter exclusivity.
• Historical formulations rely on an oil vehicle, commonly sesame oil, with antioxidant protection.
• The most practical generic strategy is a reference-like sterile vial with tightly controlled oil quality and oxidation limits.
• Preservative-free single-dose packaging and prefilled delivery systems offer the clearest product differentiation.
• Patent opportunities exist in defined excipient systems, manufacturing controls, packaging, and device combinations, not in the basic active ingredient.
• Paragraph IV risk is likely secondary to sterile manufacturing, supply continuity, and regulatory execution.
• The commercial market is a low-volume, durable generic niche with potential value in regional supply and hospital contracting.
• Biosimilar competition is not relevant because fluphenazine decanoate is a small-molecule drug.

FAQs

Can fluphenazine decanoate be formulated without sesame oil?

Yes. Alternative pharmaceutical oils may be evaluated, but the sponsor must demonstrate equivalent stability, injection performance, impurity control, release behavior, and local tolerability.

Is a preservative-free fluphenazine decanoate product commercially feasible?

Yes. A single-dose vial is the most straightforward preservative-free format. The opportunity is strongest in hospitals and outpatient clinics that value simplified sterile handling.

Can a new fluphenazine decanoate formulation receive patent protection?

Yes, if it contains a non-obvious formulation, manufacturing process, packaging system, or device combination supported by a measurable technical improvement.

Does fluphenazine decanoate require a biosimilar application?

No. It is a small-molecule drug. A generic applicant would generally use the applicable abbreviated pathway rather than a biosimilar pathway.

What is the main barrier to launching a fluphenazine decanoate generic?

The main barrier is execution in sterile injectable manufacturing. Oil quality, sterility assurance, particulate control, container compatibility, stability, and reliable supply can determine launch success more than patent expiration.

References

1. DailyMed. (n.d.). Fluphenazine decanoate injection prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
5. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Fluphenazine decanoate. National Library of Medicine.